Viking Therapeutics Inc
vikingtherapeutics.comWhat Do They Do?
Develops oral and injectable drug candidates for people with obesity and other metabolic disorders, alongside treatments for liver disease and a rare inherited neurological disorder.
10-K for FY2025, filed Feb 11, 2026We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for…View ↗
In January 2022, we announced the initiation of a Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical…View ↗
We are also developing VK2809, which is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor…View ↗
We are also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 11, 2026
How Are They Changing?
Pipeline emphasis
The earlier report centered its pipeline description on an oral liver-disease candidate; the latest report foregrounds a dual-receptor candidate for obesity in oral and injectable forms.
10-K for FY2022, filed Feb 10, 2023 10-K for FY2025, filed Feb 11, 2026Our lead clinical program’s drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid…View ↗
We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for…View ↗
In January 2022, we announced the initiation of a Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical…View ↗
Activation of the GLP-1 receptor has been shown to decrease glucose, reduce appetite, lower body weight and improve insulin sensitivity in…View ↗
Who Do They Compete With?
Competes with Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Amgen, Kailera Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Galectin Therapeutics, Inventiva, Gilead Sciences, Pfizer, Altimmune, Minoryx Therapeutics, Neuraxpharm Group, Poxel, Biophytis, Helsinn Group, Structure Therapeutics, Terns Pharmaceuticals, and Zealand Pharma
10-K for FY2025, filed Feb 11, 2026VK2735, if approved, will compete against therapies that are already approved and marketed for obesity, including Semaglutide (Wegovy®) and…View ↗
Loading...
